Allergan, Inc.  

(Public, NYSE:AGN)   Watch this stock  
Find more results for AGN
87.64
+5.57 (6.79%)
Real-time:   12:12PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 82.81 - 91.94
52 week 69.40 - 97.09
Open 84.85
Vol / Avg. 6.35M/2.09M
Mkt cap 26.60B
P/E 27.00
Div/yield 0.05/0.23
EPS 3.25
Shares 303.49M
Beta 0.80
Inst. own 93%
Aug 1, 2012
Q2 2012 Allergan Earnings Conference Call
Aug 1, 2012
Q2 2012 Allergan Earnings Release
May 16, 2012
Allergan at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin 16.55% 17.31%
Operating margin 25.46% 25.13%
EBITD margin - 29.81%
Return on average assets 10.75% 11.16%
Return on average equity 17.12% 18.57%
Employees 10,000 -
Carbon Disclosure Rating - 83/100

Address

2525 Dupont Drive
IRVINE, CA 92612
United States - Map
+1-714-2464500 (Phone)
+1-714-2466987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia
Discussion Group - Google Finance

Description

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company operates in two segments: specialty pharmaceuticals and medical devices. The Company discovers, develops and commercializes a diverse range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries. In May 2011, a generic version of Elestat was launched in the United States. On June 17, 2011, it acquired Alacer Biomedical, Inc. (Alacer). On August 8, 2011, it acquired Precision Light, Inc. (Precision Light). On July 22, 2011, it acquired Vicept Therapeutics, Inc. (Vicept). During the year ended December, 31, 2011, it discontinued its EasyBand Remote Adjustable Gastric Band System. In February 2011, it discontinued the United States sales of Zymar.

Officers and directors

David E.I. Pyott Chairman of the Board, President, Chief Executive Officer, Principal Executive Officer
Age: 58
Bio & Compensation - Reuters
Herbert W. Boyer Ph.D. Vice Chairman of the Board, Lead Independent Director
Age: 75
Bio & Compensation - Reuters
Jeffrey L. Edwards CFO, PFO, Executive Vice President - Finance and Business Development
Age: 51
Bio & Compensation - Reuters
Scott M. Whitcup M.D. Executive Vice President - Reseach & Development, Chief Scientific Officer
Age: 52
Bio & Compensation - Reuters
Arnold A. Pinkston Executive Vice President, General Counsel, Assistant Secretary
Age: 53
Bio & Compensation - Reuters
Scott D. Sherman Executive Vice President - Human Resources
Age: 46
Bio & Compensation - Reuters
Raymond H. Diradoorian Executive Vice President - Global Technical Operations
Age: 54
Bio & Compensation - Reuters
Douglas S. Ingram Esq. Executive Vice President and President, Europe, Africa, Middle East
Age: 49
Bio & Compensation - Reuters
James F. Barlow Senior Vice President, Corporate Controller, Principal Accounting Officer
Age: 53
Bio & Compensation - Reuters
David J. Endicott Corporate Vice President and President of Allergan Medical, Asia Pacific and Latin America
Age: 47
Bio & Compensation - Reuters